Do analysts prefer EDIT or TLSA?

Editas Medicine currently has a consensus price target of $5.50, suggesting a potential upside of 74.05%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, EDIT or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Editas Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Editas Medicine $40.52M 11.98 -$160.06M -$0.75 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media refer more to EDIT or TLSA?

In the previous week, Editas Medicine had 14 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 18 mentions for Editas Medicine and 4 mentions for Tiziana Life Sciences. Editas Medicine's average media sentiment score of 1.10 beat Tiziana Life Sciences' score of 0.47 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PRTA or TLSA?

Prothena presently has a consensus target price of $24.57, suggesting a potential upside of 163.36%. Given Prothena's stronger consensus rating and higher probable upside, research analysts plainly believe Prothena is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, PRTA or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 50.46 -$244.09M -$0.84 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor PRTA or TLSA?

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Prothena. Prothena's average media sentiment score of 1.61 beat Tiziana Life Sciences' score of 0.47 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate EVMN or TLSA?

Evommune presently has a consensus price target of $41.56, suggesting a potential upside of 218.43%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evommune 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.80 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, EVMN or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 36.43 -$68.87M -$11.03 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is EVMN or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Tiziana Life Sciences N/A N/A N/A

Does the media favor EVMN or TLSA?

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat Tiziana Life Sciences' score of 0.47 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CCCC or TLSA?

C4 Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 101.30%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe C4 Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, CCCC or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than C4 Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio C4 Therapeutics $35.95M 13.18 -$104.99M -$1.00 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor CCCC or TLSA?

In the previous week, C4 Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for C4 Therapeutics and 4 mentions for Tiziana Life Sciences. C4 Therapeutics' average media sentiment score of 1.11 beat Tiziana Life Sciences' score of 0.47 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AGMB or TLSA?

AgomAb Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 184.74%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, AGMB or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is AGMB or TLSA more profitable?

Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Tiziana Life Sciences N/A N/A N/A

Does the media favor AGMB or TLSA?

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 4 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.72 beat Tiziana Life Sciences' score of 0.47 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tiziana Life Sciences (TLSA) Competitors

$1.01 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$0.99 -0.02 (-1.88%)

As of 04:02 AM Eastern

Compare

TLSA vs. EDIT, PRTA, EVMN, CCCC, and AGMB

Should you buy Tiziana Life Sciences stock or one of its competitors? Tiziana Life Sciences's main competitors and comparable companies include Editas Medicine (EDIT), Prothena (PRTA), Evommune (EVMN), C4 Therapeutics (CCCC), and AgomAb Therapeutics (AGMB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tiziana Life Sciences compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

71.9% of Editas Medicine shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Editas Medicine had 14 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 18 mentions for Editas Medicine and 4 mentions for Tiziana Life Sciences. Editas Medicine's average media sentiment score of 1.10 beat Tiziana Life Sciences' score of 0.47 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine currently has a consensus price target of $5.50, suggesting a potential upside of 74.05%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tiziana Life Sciences has lower revenue, but higher earnings than Editas Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.98	-$160.06M	-$0.75	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Tiziana Life Sciences' return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Tiziana Life Sciences	N/A	N/A	N/A

Summary

Editas Medicine beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Prothena?

Prothena (NASDAQ:PRTA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Tiziana Life Sciences has lower revenue, but higher earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	50.46	-$244.09M	-$0.84	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Prothena has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Tiziana Life Sciences' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Tiziana Life Sciences	N/A	N/A	N/A

Prothena presently has a consensus target price of $24.57, suggesting a potential upside of 163.36%. Given Prothena's stronger consensus rating and higher probable upside, research analysts plainly believe Prothena is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Prothena. Prothena's average media sentiment score of 1.61 beat Tiziana Life Sciences' score of 0.47 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Prothena and Tiziana Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Evommune?

Evommune (NYSE:EVMN) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Tiziana Life Sciences has lower revenue, but higher earnings than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	36.43	-$68.87M	-$11.03	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Evommune presently has a consensus price target of $41.56, suggesting a potential upside of 218.43%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tiziana Life Sciences' return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 2 mentions for Evommune. Evommune's average media sentiment score of 0.89 beat Tiziana Life Sciences' score of 0.47 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evommune beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.

How does Tiziana Life Sciences compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

C4 Therapeutics presently has a consensus target price of $7.75, suggesting a potential upside of 101.30%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe C4 Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

C4 Therapeutics has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

78.8% of C4 Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has lower revenue, but higher earnings than C4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	13.18	-$104.99M	-$1.00	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. Tiziana Life Sciences' return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, C4 Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for C4 Therapeutics and 4 mentions for Tiziana Life Sciences. C4 Therapeutics' average media sentiment score of 1.11 beat Tiziana Life Sciences' score of 0.47 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

C4 Therapeutics beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

In the previous week, AgomAb Therapeutics and AgomAb Therapeutics both had 4 articles in the media. AgomAb Therapeutics' average media sentiment score of 0.72 beat Tiziana Life Sciences' score of 0.47 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

AgomAb Therapeutics currently has a consensus price target of $37.50, indicating a potential upside of 184.74%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Tiziana Life Sciences	N/A	N/A	N/A

Summary

AgomAb Therapeutics beats Tiziana Life Sciences on 4 of the 5 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSA vs. The Competition

Export

Metric	Tiziana Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$128.53M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	N/A	11.68	273.17	25.45
Price / Sales	N/A	1,408.89	638.21	103.75
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	N/A	16.92	11.08	6.36
Net Income	-$18.43M	-$22.74M	$3.48B	$349.79M
7 Day Performance	-12.17%	-0.13%	0.38%	-0.40%
1 Month Performance	-1.94%	11.45%	7.89%	4.24%
1 Year Performance	-44.20%	55.66%	24.71%	15.13%

Tiziana Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSA Tiziana Life Sciences	1.3726 of 5 stars	$1.01 flat	N/A	-44.2%	$128.53M	N/A	N/A	8	Positive News
EDIT Editas Medicine	2.0376 of 5 stars	$3.34 +1.2%	$5.50 +64.7%	+23.0%	$512.96M	$40.52M	N/A	230	Trending News Analyst Revision
PRTA Prothena	2.8895 of 5 stars	$9.35 +2.9%	$24.57 +162.8%	+13.8%	$489.50M	$54.53M	N/A	130	Positive News
EVMN Evommune	2.9236 of 5 stars	$13.36 -0.9%	$41.56 +211.0%	N/A	$484.83M	$13M	N/A	45
CCCC C4 Therapeutics	1.6721 of 5 stars	$3.92 -4.4%	$7.75 +97.7%	+48.1%	$482.28M	$35.95M	N/A	150	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. EDIT, PRTA, EVMN, CCCC, and AGMB

How does Tiziana Life Sciences compare to Editas Medicine?

Summary

How does Tiziana Life Sciences compare to Prothena?

Summary

How does Tiziana Life Sciences compare to Evommune?

Summary

How does Tiziana Life Sciences compare to C4 Therapeutics?

Summary

How does Tiziana Life Sciences compare to AgomAb Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. EDIT, PRTA, EVMN, CCCC, and AGMB

How does Tiziana Life Sciences compare to Editas Medicine?

Do institutionals and insiders hold more shares of EDIT or TLSA?

Does the media refer more to EDIT or TLSA?

Do analysts prefer EDIT or TLSA?

Which has higher valuation and earnings, EDIT or TLSA?

Which has more risk and volatility, EDIT or TLSA?

Is EDIT or TLSA more profitable?

Summary

How does Tiziana Life Sciences compare to Prothena?

Which has stronger earnings and valuation, PRTA or TLSA?

Which has more risk and volatility, PRTA or TLSA?

Is PRTA or TLSA more profitable?

Do analysts prefer PRTA or TLSA?

Does the media favor PRTA or TLSA?

Do insiders and institutionals hold more shares of PRTA or TLSA?

Summary

How does Tiziana Life Sciences compare to Evommune?

Which has preferable earnings & valuation, EVMN or TLSA?

Do analysts rate EVMN or TLSA?

Is EVMN or TLSA more profitable?

Does the media favor EVMN or TLSA?

Summary

How does Tiziana Life Sciences compare to C4 Therapeutics?

Do analysts recommend CCCC or TLSA?

Which has more volatility & risk, CCCC or TLSA?

Do insiders and institutionals believe in CCCC or TLSA?

Which has preferable earnings & valuation, CCCC or TLSA?

Is CCCC or TLSA more profitable?

Does the media favor CCCC or TLSA?

Summary

How does Tiziana Life Sciences compare to AgomAb Therapeutics?

Does the media favor AGMB or TLSA?

Which has stronger valuation & earnings, AGMB or TLSA?

Do analysts recommend AGMB or TLSA?

Is AGMB or TLSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools